New Delaware Chapter 11 Filing – BIND Therapeutics, Inc. et al.
BIND Therapeutics, Inc. (Nasdaq – BIND), a clinical-stage nanomedicine platform company development novel targeted therapeutic, primarily for the treatment of cancer, and its affiliate BIND Biosciences Security Corporation, have filed a chapter 11 petitions before the United States Bankruptcy Court for the District of Delaware (Lead Case No. 16-11084). The cases have been assigned to the Honorable Brendan L. Shannon. The debtors have filed a motion seeking authority to use cash collateral. The petitions (including the consolidated list of top 26 creditors), the first day declaration and the docket are available through Prime Clerk. The debtors have issued a press release regarding their reorganization efforts.
As the law continues to evolve on these matters, please note that this article is current as of date and time of publication and may not reflect subsequent developments. The content and interpretation of the issues addressed herein is subject to change. Cole Schotz P.C. disclaims any and all liability with respect to actions taken or not taken based on any or all of the contents of this publication to the fullest extent permitted by law. This is for general informational purposes and does not constitute legal advice or create an attorney-client relationship. Do not act or refrain from acting upon the information contained in this publication without obtaining legal, financial and tax advice. For further information, please do not hesitate to reach out to your firm contact or to any of the attorneys listed in this publication.
Join Our Mailing List
Stay up to date with the latest insights, events, and more